ClinicalTrials.gg
CompletedNCT01447420Updated Jul 25, 2016Results posted

A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

A Phase 4 interventional study of peginterferon alfa-2a and ribavirin [Copegus] in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 15 sites in Brazil. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2016-07-25.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
129
Allocation
Not applicable
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
42nd of 83
129 · median 129
Started
2011
with 6 others
Phase 4
48 of 83
none open now
Registered
63rd of 83
by date
Lead sponsor
35 of 83
Hoffmann-La Roche

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 42nd largest by enrollment, is one of 7 that started in 2011, is one of 48 in phase 4, and was the 63rd registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This multi-center, open-label study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in relation to IL28-b gene expression in treatment-naïve patients with chronic hepatitis C genotype 1. Patients will receive Pegasys (180 mcg sc weekly) and Copegus ( 1'000 or 1'200 mg orally daily) for 48 weeks. Anticipated time of study treatment is 48 weeks, follow-up is 24 weeks.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/=18 and \<70 years of age at initiation of treatment
  • Body weight between 50 kg and 125 kg at baseline
  • Chronic , genotype 1
  • Chronic liver disease consistent with HCV infection
  • Compensated liver disease ( Grade A)

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women, and male partners of pregnant women
  • Chronic , genotype 2, 3, 4, 5 or 6
  • Previous treatment with interferon or ribavirin
  • Positive for hepatitis A, or infection
  • History or evidence of a medical condition associated with liver disease other than chronic hepatitis C
  • Decompensated liver disease and/or liver disease classification >6
  • Hepatocellular carcinoma
  • History or evidence of esophageal bleeding
  • Hemoglobinopathy, or any other cause for possible hemolysis
  • \<11 g/dL in women, \<12 g/L in males
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Peginterferon Alfa-2a Plus Ribavirin

    Drug: peginterferon alfa-2a · Drug: ribavirin [Copegus]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virological Response Rate in Relation to Interleukin 28B Expression

    Participants with sustained virological response (SVR) rate in relation to interleukin 28B expression were reported. SVR rate is defined as the percentage of participants with undetectable HCV Ribonucleic acid (RNA), measured at least 24 weeks after the end of treatment (48 weeks) in terms of the expression profile of Interleukin 28B (IL-28B) (CC, CT or TT) in participants with genotype 1 hepatitis C virus (HCV) chronic infection. Participants with detectable HCV RNA or without measurement at the end of the follow-up period were considered as non-responders.

    Time frame: At Week 72

  2. Percentage of Participants With Incidence of Anemia

    Anemia is a condition marked by a deficiency of red blood cells (RBCs) or of hemoglobin (Hb) in the blood, resulting in pallor and weariness anemia (Hb \< 11 gram per decilitre (g/dL) for women and Hb \< 12 g/dL for men). Incidence of anemia was calculated by dividing the number of participants who experienced the event by the number of participants in the safety population.

    Time frame: Up to Week 72

Secondary outcomes

  1. Number of Participants With Viral Response Rate (Rapid/Early/End of Treatment) in Relation to IL28-B Expression

    Viral Response rate (rapid/early/end of treatment) in relation to IL28-B expression (measured by the rate of non-detection of HCV RNA at treatment Weeks 4, 12, 24 and after the End of Treatment (EOT, i.e. Week 48) based on the expression profile of IL-28B (CC, CT or TT) were reported. Rapid virologic response (RVR) was defined as undetectable HCV RNA at treatment Week 4. Partial early virological response (pEVR) was defined as positive HCV viral load, but with a \>= 2 log10 international units (IU) per millilitre (mL) reduction at treatment Week 12 from Baseline (Week 0); Complete early virologic response (cEVR) was defined as undetectable HCV RNA at treatment Week 12; Virologic response at treatment Week 24 (VR 24) was defined as undetectable HCV RNA at treatment Week 24; Virologic response at end of treatment (EOT) was defined as undetectable HCV RNA at treatment Week 48; SVR at 24 weeks after end of treatment was defined as undetectable HCV RNA at 24 weeks after EOT.

    Time frame: Weeks 4, 12, 24, 48, 60 and 72

  2. Number of Participants With Sustained Virological Response and Occurrence of Anemia During The First Month of Treatment and After the First Month of Treatment

    Participants with sustained virological response (SVR) and development of anemia during the first month and after the first month of treatment according to the different expression profiles of IL-28B were reported.

    Time frame: Up to Week 72

  3. Number of Participants With Viral Load Reduction (HCV-RNA Levels) at Week 4 and 12

    Viral load reduction at Week 4 and Week 12 relative to the Baseline (Week 0) in terms of the expression profile of IL-28b was reported. The reduction was measured according to the following ranges: \< 1.0 log IU/ml; \>= 1.0 and \< 2.0 log IU/ml; \>= 2.0 and \< 3.0 log IU/ml; \>= 3.0 and \<4.0 log IU/ml; \>= 4.0 log IU/ml. Changes in viral load are usually reported as a log change (in powers of 10). For example, a two log decrease in viral load (2 Log10) is a decrease of 10\^2 or 100 times to the previously reported levels. N = number of participants, for Week 0 to Week 4 (n = 34, 68, 17) and Week 0 to Week 12 (n = 35, 69, 18) for CC, CT and TT genotypes respectively.

    Time frame: From Baseline (Week 0) to Week 12

07

Results

Posted Jun 24, 2016

Participant flow

A total of 129 participants were enrolled from February 2011 to November 2012 at 14 study sites in Brazil.

Participant flow — Overall Study
MilestonePeginterferon Alfa-2a Plus Ribavirin With Genotype - CCPeginterferon Alfa-2a Plus Ribavirin With Genotype - CTPeginterferon Alfa-2a Plus Ribavirin With Genotype - TT
Started397218
Completed29458
Not completed102710
Withdrew: Adverse event242
Withdrew: Protocol violation330
Withdrew: Withdrawal by subject410
Withdrew: Lack of efficacy1198

Outcome measures

PrimaryPercentage of Participants With Sustained Virological Response Rate in Relation to Interleukin 28B Expression

Participants with sustained virological response (SVR) rate in relation to interleukin 28B expression were reported. SVR rate is defined as the percentage of participants with undetectable HCV Ribonucleic acid (RNA), measured at least 24 weeks after the end of treatment (48 weeks) in terms of the expression profile of Interleukin 28B (IL-28B) (CC, CT or TT) in participants with genotype 1 hepatitis C virus (HCV) chronic infection. Participants with detectable HCV RNA or without measurement at the end of the follow-up period were considered as non-responders.

Time frame:
At Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Virological Response Rate in Relation to Interleukin 28B Expression
Percentage of participantsPeginterferon Alfa-2a Plus Ribavirin With Genotype - CCPeginterferon Alfa-2a Plus Ribavirin With Genotype - CTPeginterferon Alfa-2a Plus Ribavirin With Genotype - TT
Percentage of Participants With Sustained Virological Response Rate in Relation to Interleukin 28B Expression63.2 (46.0 to 78.2)26.4 (16.7 to 38.1)33.3 (13.3 to 59.0)
Statistical analysis
  • Peginterferon Alfa-2a Plus Ribavirin With Genotype - CC vs Peginterferon Alfa-2a Plus Ribavirin With Genotype - CT vs Peginterferon Alfa-2a Plus Ribavirin With Genotype - TT · Chi-squared · p = 0.0007Participants without measurement at the end of the 24 week untreated follow-up period were considered as non-responders.
PrimaryPercentage of Participants With Incidence of Anemia

Anemia is a condition marked by a deficiency of red blood cells (RBCs) or of hemoglobin (Hb) in the blood, resulting in pallor and weariness anemia (Hb \< 11 gram per decilitre (g/dL) for women and Hb \< 12 g/dL for men). Incidence of anemia was calculated by dividing the number of participants who experienced the event by the number of participants in the safety population.

Time frame:
Up to Week 72
Reported as:
Number · Percentage of participants
Percentage of Participants With Incidence of Anemia
Percentage of participantsPeginterferon Alfa-2a Plus Ribavirin
Percentage of Participants With Incidence of Anemia67.4 (58.6 to 75.4)
SecondaryNumber of Participants With Viral Response Rate (Rapid/Early/End of Treatment) in Relation to IL28-B Expression

Viral Response rate (rapid/early/end of treatment) in relation to IL28-B expression (measured by the rate of non-detection of HCV RNA at treatment Weeks 4, 12, 24 and after the End of Treatment (EOT, i.e. Week 48) based on the expression profile of IL-28B (CC, CT or TT) were reported. Rapid virologic response (RVR) was defined as undetectable HCV RNA at treatment Week 4. Partial early virological response (pEVR) was defined as positive HCV viral load, but with a \>= 2 log10 international units (IU) per millilitre (mL) reduction at treatment Week 12 from Baseline (Week 0); Complete early virologic response (cEVR) was defined as undetectable HCV RNA at treatment Week 12; Virologic response at treatment Week 24 (VR 24) was defined as undetectable HCV RNA at treatment Week 24; Virologic response at end of treatment (EOT) was defined as undetectable HCV RNA at treatment Week 48; SVR at 24 weeks after end of treatment was defined as undetectable HCV RNA at 24 weeks after EOT.

Time frame:
Weeks 4, 12, 24, 48, 60 and 72
Reported as:
Number · participants
Number of Participants With Viral Response Rate (Rapid/Early/End of Treatment) in Relation to IL28-B Expression
participantsPeginterferon Alfa-2a Plus Ribavirin With Genotype - CCPeginterferon Alfa-2a Plus Ribavirin With Genotype - CTPeginterferon Alfa-2a Plus Ribavirin With Genotype - TT
RVR rate, Week 4 (n = 14)1130
pEVR rate, Week 12 (n = 33)4245
cEVR rate, Week 12 (n = 72)31365
VR rate, Week 24 (n = 87)314610
VR rate, EOT (Week 48) (n = 74)28379
VR rate, 12 weeks post-treatment (n = 50)25196
SVR rate, 24 weeks or more post-treatment (n = 49)24196
SecondaryNumber of Participants With Sustained Virological Response and Occurrence of Anemia During The First Month of Treatment and After the First Month of Treatment

Participants with sustained virological response (SVR) and development of anemia during the first month and after the first month of treatment according to the different expression profiles of IL-28B were reported.

Time frame:
Up to Week 72
Reported as:
Number · participants
Number of Participants With Sustained Virological Response and Occurrence of Anemia During The First Month of Treatment and After the First Month of Treatment
participantsPeginterferon Alfa-2a Plus Ribavirin With Genotype - CCPeginterferon Alfa-2a Plus Ribavirin With Genotype - CTPeginterferon Alfa-2a Plus Ribavirin With Genotype - TT
SVR with No anemia (n = 15, 20, 6)942
In the first month of treatment (n = 10, 15, 2)630
After the first month of treatment (n = 13, 37,10)9124
Statistical analysis
  • Peginterferon Alfa-2a Plus Ribavirin With Genotype - CC vs Peginterferon Alfa-2a Plus Ribavirin With Genotype - CT vs Peginterferon Alfa-2a Plus Ribavirin With Genotype - TT · Odds ratio (or): 1.68 · 95% CI 0.69 to 4.14Odds Ratio for SVR estimated from the logistic regression model.
  • Peginterferon Alfa-2a Plus Ribavirin With Genotype - CC vs Peginterferon Alfa-2a Plus Ribavirin With Genotype - CT vs Peginterferon Alfa-2a Plus Ribavirin With Genotype - TT · Odds ratio (or): 0.86 · 95% CI 0.28 to 2.59Odds Ratio for SVR estimated from the logistic regression model.
  • Peginterferon Alfa-2a Plus Ribavirin With Genotype - CC vs Peginterferon Alfa-2a Plus Ribavirin With Genotype - CT · Odds ratio (or): 5.45 · 95% CI 2.27 to 13.12Odds Ratio for SVR estimated from the logistic regression model.
  • Peginterferon Alfa-2a Plus Ribavirin With Genotype - CC vs Peginterferon Alfa-2a Plus Ribavirin With Genotype - TT · Odds ratio (or): 4.03 · 95% CI 1.19 to 13.61Odds Ratio for SVR estimated from the logistic regression model.
SecondaryNumber of Participants With Viral Load Reduction (HCV-RNA Levels) at Week 4 and 12

Viral load reduction at Week 4 and Week 12 relative to the Baseline (Week 0) in terms of the expression profile of IL-28b was reported. The reduction was measured according to the following ranges: \< 1.0 log IU/ml; \>= 1.0 and \< 2.0 log IU/ml; \>= 2.0 and \< 3.0 log IU/ml; \>= 3.0 and \<4.0 log IU/ml; \>= 4.0 log IU/ml. Changes in viral load are usually reported as a log change (in powers of 10). For example, a two log decrease in viral load (2 Log10) is a decrease of 10\^2 or 100 times to the previously reported levels. N = number of participants, for Week 0 to Week 4 (n = 34, 68, 17) and Week 0 to Week 12 (n = 35, 69, 18) for CC, CT and TT genotypes respectively.

Time frame:
From Baseline (Week 0) to Week 12
Reported as:
Number · participants
Number of Participants With Viral Load Reduction (HCV-RNA Levels) at Week 4 and 12
participantsPeginterferon Alfa-2a Plus Ribavirin With Genotype - CCPeginterferon Alfa-2a Plus Ribavirin With Genotype - CTPeginterferon Alfa-2a Plus Ribavirin With Genotype - TT
Week 0 - Week 4 (<1.0 log10 UI / ml)02610
Week 0 - Week 4 (>=1.0 e < 2.0 log10 UI / ml)4245
Week 0 - Week 4 (>=2.0 e < 3.0 log10 UI / ml)9131
Week 0 - Week 4 (>=3.0 e < 4.0 log10 UI / ml)1321
Week 0 - Week 4 (>=4.0 log10 UI / ml)830
Week 0 - Week 12 (<1.0 log10 UI / ml)013
Week 0 - Week 12 (>=1.0 e < 2.0 log10 UI / ml)395
Week 0 - Week 12 (>=2.0 e < 3.0 log10 UI / ml)5113
Week 0 - Week 12 (>=3.0 e < 4.0 log10 UI / ml)5223
Week 0 - Week 12 (>=4.0 log10 UI / ml)22264

Adverse events

Collected over Up to Week 72. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peginterferon Alfa-2a Plus Ribavirin—6/129 (4.7%)125/129 (96.9%)
Most frequent serious events
Most frequent serious events
EventPeginterferon Alfa-2a Plus Ribavirin
Chest painCardiac disorders1/129
Optic ischaemic neuropathyEye disorders1/129
Retinal vascular disorderEye disorders1/129
Perianal erythemaGastrointestinal disorders1/129
Hepatic encephalopathyNervous system disorders1/129
Anxiety disorderPsychiatric disorders1/129
AsthmaRespiratory, thoracic and mediastinal disorders1/129
PneumoniaRespiratory, thoracic and mediastinal disorders1/129
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPeginterferon Alfa-2a Plus Ribavirin
HeadacheNervous system disorders55/129
InfluenzaInfections and infestations54/129
PyrexiaGeneral disorders48/129
MyalgiaMusculoskeletal and connective tissue disorders42/129
AnaemiaBlood and lymphatic system disorders41/129
AstheniaGeneral disorders35/129
NauseaGastrointestinal disorders32/129
DiarrhoeaGastrointestinal disorders25/129
InsomniaPsychiatric disorders25/129
IrritabilityPsychiatric disorders25/129

Baseline characteristics

Safety population included all enrolled participants who received at least one dose of any study medication.

Age, Continuous
Age, Continuous(years)Peginterferon Alfa-2a Plus Ribavirin With Genotype - CCPeginterferon Alfa-2a Plus Ribavirin With Genotype - CTPeginterferon Alfa-2a Plus Ribavirin With Genotype - TTTotal
Mean48.51 ± 12.7150.43 ± 10.9252.33 ± 10.2250.12 ± 11.38
Sex: Female, Male
Sex: Female, Male(Participants)Peginterferon Alfa-2a Plus Ribavirin With Genotype - CCPeginterferon Alfa-2a Plus Ribavirin With Genotype - CTPeginterferon Alfa-2a Plus Ribavirin With Genotype - TTTotal
Female2233964
Male1739965
08

Study locations

15 sites
  • Salvador, BA 41110-170, Brazil
  • Vitoria, ES 29043-260, Brazil
  • Juiz de Fora, MG 36038-330, Brazil
  • Rio de Janeiro, RJ 20020-022, Brazil
  • Rio de Janeiro, RJ 20270-004, Brazil
  • Joinville, SC 89202-050, Brazil
  • Sao Jose Do Rio Preto, SC 15090-000, Brazil
  • Botucatu, SP 18600-400, Brazil
  • Campinas, SP 13026-210, Brazil
  • Campinas, SP 13060-803, Brazil
  • Santos, SP 11015470, Brazil
  • Sao Paulo, SP 04040-003, Brazil
  • Sao Paulo, SP 04119-001, Brazil
  • Sao Paulo, SP 04266-010, Brazil
  • Sorocaba, SP 18047-600, Brazil
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2011
First posted
Oct 6, 2011
Start
Feb 2011
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
Jun 24, 2016
Last update
Jul 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01447420
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 6, 2011
Start date
Feb 2011
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Jun 24, 2016
Last update
Jul 25, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion